424B3 1 ss30532_424b3.htm
 
   
PROSPECTUS SUPPLEMENT
REGISTRATION NO.  333-89355
(To Prospectus dated August 15, 2007)
Filed Pursuant to Rule 424(b)(3)

 
 
1,000,000,000 Depositary Receipts
Biotech HOLDRS (SM) Trust
 
This prospectus supplement supplements information contained in the prospectus dated August 15, 2007 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust.
 
The share amounts specified in the table in the “Highlights of Biotech HOLDRS” section of the base prospectus shall be replaced with the following:
 
Name of Company
 
Ticker
 
Share
Amounts
 
Primary
Trading
Market
Affymetrix, Inc.
 
AFFX
 
4
 
NASDAQ
Alkermes, Inc.
 
ALKS
 
4
 
NASDAQ
Amgen Inc.
 
AMGN
 
64.48
 
NASDAQ
Applera Corporation—Applied Biosystems Group*
 
ABI
 
18
 
NYSE
Applera Corporation—Celera Genomics Group*
 
CRA
 
4
 
NYSE
Biogen IDEC Inc.
 
BIIB
 
26.95
 
NASDAQ
Enzon Pharmaceuticals, Inc.
 
ENZN
 
3
 
NASDAQ
Genentech, Inc.
 
DNA
 
88
 
NYSE
Genzyme Corporation
 
GENZ
 
14
 
NASDAQ
Gilead Sciences, Inc.
 
GILD
 
64
 
NASDAQ
Human Genome Sciences, Inc.
 
HGSI
 
8
 
NASDAQ
Millennium Pharmaceuticals, Inc.
 
MLNM
 
12
 
NASDAQ
QLT Inc.
 
QLTI
 
5
 
NASDAQ
Sepracor Inc.
 
SEPR
 
6
 
NASDAQ
Shire p.l.c.
 
SHPGY
 
6.8271
 
NASDAQ

 
*  The securities of this company trade as a tracking stock.  Please see “Risk Factors” and the business description in Annex A for additional information relating to an investment in tracking stock.

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is December 31, 2007.